Combination

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Tuesday, November 7, 2023

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.

Key Points: 
  • DUET-102 is a double-stranded antisense oligonucleotide (“ASO”) STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma.
  • Glioma is a common type of tumor originating in the glial cells of the brain.
  • DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma.
  • There is an acute need for new treatment options for glioma, which have seen no significant advances in the past decade.

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to December 3, 2023

Retrieved on: 
Friday, November 3, 2023

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced that on November 2, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023 (the “Extension”).

Key Points: 
  • MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced that on November 2, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023 (the “Extension”).
  • The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This is the first of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination

Retrieved on: 
Friday, November 3, 2023

ATLANTA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”), upon request by Altitude’s sponsor, Altitude Acquisition Holdco LLC (the “Sponsor”), has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from November 11, 2023 to December 11, 2023.

Key Points: 
  • ATLANTA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”), upon request by Altitude’s sponsor, Altitude Acquisition Holdco LLC (the “Sponsor”), has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from November 11, 2023 to December 11, 2023.
  • On November 3, 2023, pursuant to the Charter and upon request from the Sponsor, the Board determined to implement an eighth Extension.
  • As previously announced, on April 23, 2023, Altitude entered into a business combination agreement (the “Business Combination Agreement”) with Picard Medical, Inc. (“Picard”) and the other parties thereto, which provides for a business combination between Altitude and Picard.
  • The purpose of this monthly Extension is to provide Altitude with additional time to consummate the proposed business combination with Picard.

Notice of Extraordinary General Meeting of Shareholders

Retrieved on: 
Tuesday, October 31, 2023

Only shareholders of record at the close of business on November 6, 2023, are entitled to notice of and to vote at the Meeting or at any adjournment thereof.

Key Points: 
  • Only shareholders of record at the close of business on November 6, 2023, are entitled to notice of and to vote at the Meeting or at any adjournment thereof.
  • On October 30, 2023, Symetryx publicly filed a notice attempting to convene an extraordinary general meeting of shareholders of the Company for Monday, December 4, 2023, at 4:00pm, Israel time, for the replacement of Check-Cap’s Board, pursuant to Section 64 of the Companies Law.
  • We believe that under such circumstances, it is evident that the Company (and its shareholders) will not be harmed by including both matters on the agenda of a single extraordinary general meeting of shareholders; therefore, there is no need or justification for compelling the Check-Cap Board to convene an additional, separate extraordinary general meeting of shareholders specifically for director elections, within a matter of a few days or weeks prior to the date of the extraordinary general meeting that will be convened for the approval of the Keystone transaction, with all the associated costs.
  • At least two shareholders present, in person or by proxy, will constitute a quorum at the adjourned meeting.

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to December 3, 2023

Retrieved on: 
Tuesday, October 31, 2023

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by November 3, 2023 (the “Extension”).

Key Points: 
  • MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by November 3, 2023 (the “Extension”).
  • In connection with the Extension, the Company intends to issue to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This will be the first of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

Retrieved on: 
Tuesday, October 31, 2023

The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.
  • The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected to drive market growth.
  • At the same time, opioid abuse and addiction has been a global growing epidemic for more than a decade.
  • "The fact that SciSparc's number of granted patents continues to grow is proof recognizing the innovation that characterizes the technologies in the Company's pipeline.

Enhanc3D Genomics Expands Leadership Team With the Appointment of Hazel Jones as Chief Operating Officer

Retrieved on: 
Monday, November 6, 2023

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.
  • Hazel has over 10 years of senior leadership experience in oncology research.
  • Prior to joining Enhanc3D Genomics, Hazel held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D.
  • I am delighted to welcome Hazel to the team.”
    Dr Hazel Jones, Chief Operating Officer, Enhanc3D Genomics, added: “I’m delighted to join the team at such an exciting stage of the Company’s development, and to support Enhanc3D’s vision to ultimately improve outcomes for patients through more targeted treatment options.”
    For more information about Enhanc3D Genomics, please visit: www.enhanc3dgenomics.com

Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I

Retrieved on: 
Friday, November 3, 2023

Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that it notified Healthwell Acquisition Corp.

Key Points: 
  • Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that it notified Healthwell Acquisition Corp.
  • I (NASDAQ: HWEL) (“Healthwell”) today that the Company had elected to terminate the business combination agreement among Starton, Healthwell and the other parties thereto dated as of April 27, 2023, as amended (the “Combination Agreement”), effective immediately.
  • The conditions to the closing of the initial business combination and subsequent amendments were not satisfied or waived by the outside date of November 3 2023 (the “Termination”).
  • “Over the last several months, Starton has taken significant, critical steps forward in its clinical development,” said Pedro Lichtinger, Chairman and CEO of Starton Therapeutics.

Renesas’ New Ultra-High Performance MCUs are Industry’s First Based on Arm Cortex-M85 Processor

Retrieved on: 
Tuesday, October 31, 2023

The new RA8 Series MCUs are the industry’s first to implement the Arm® Cortex®-M85 processor, enabling the new devices to deliver industry-leading 6.39 CoreMark/MHz1 performance.

Key Points: 
  • The new RA8 Series MCUs are the industry’s first to implement the Arm® Cortex®-M85 processor, enabling the new devices to deliver industry-leading 6.39 CoreMark/MHz1 performance.
  • This level of performance will allow system designers to use the RA MCUs in applications that previously required microprocessors (MPUs).
  • The new series is part of Renesas’ popular RA Family of MCUs based on Arm Cortex processors.
  • View the full release here: https://www.businesswire.com/news/home/20231031195413/en/
    The new RA8 Series MCUs deploy Arm Helium™ technology, Arm’s M-Profile Vector Extension that provides up to a 4X performance boost for digital signal processor (DSP) and machine learning (ML) implementations versus MCUs based on the Arm Cortex-M7 processor.

X-energy and Ares Acquisition Corporation Mutually Agree to Terminate Business Combination Agreement

Retrieved on: 
Tuesday, October 31, 2023

X-Energy Reactor Company, LLC (“X-energy”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation (NYSE: AAC) (“AAC”), a publicly-traded special purpose acquisition company, announced today that they have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”), effective immediately.

Key Points: 
  • X-Energy Reactor Company, LLC (“X-energy”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation (NYSE: AAC) (“AAC”), a publicly-traded special purpose acquisition company, announced today that they have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”), effective immediately.
  • Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the business combination agreement.
  • In view of the termination of the Business Combination Agreement, AAC determined that it will not be able to consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (as amended, the “Articles”).
  • As of November 6, 2023, AAC will cease all operations except those required to wind up AAC’s business.